It	O
is	O
the	O
main	O
road	O
that	O
gives	O
access	O
to	O
the	O
Jodrell	other-medical
Bank	other-medical
Observatory	other-medical
and	O
the	O
Quinta	other-medical
Arboretum	other-medical
,	O
planted	O
by	O
Sir	O
Bernard	person-other
Lovell	person-other
in	O
1948	O
.	O

The	O
chemical	O
name	O
of	O
doxepin	other-medical
is	O
(	other-chemicalthing
``	other-chemicalthing
E	other-chemicalthing
''	other-chemicalthing
/	other-chemicalthing
''	other-chemicalthing
Z	other-chemicalthing
''	other-chemicalthing
)	other-chemicalthing
-3-	other-chemicalthing
(	other-chemicalthing
dibenzo	other-chemicalthing
[	other-chemicalthing
``	other-chemicalthing
b	other-chemicalthing
''	other-chemicalthing
,	other-chemicalthing
''	other-chemicalthing
e	other-chemicalthing
''	other-chemicalthing
]	other-chemicalthing
oxepin-11	other-chemicalthing
(	other-chemicalthing
6	other-chemicalthing
''	other-chemicalthing
H	other-chemicalthing
''	other-chemicalthing
)	other-chemicalthing
-ylidene	other-chemicalthing
)	other-chemicalthing
-	other-chemicalthing
''	other-chemicalthing
N	other-chemicalthing
''	other-chemicalthing
,	other-chemicalthing
''	other-chemicalthing
N	other-chemicalthing
''	other-chemicalthing
-dimethylpropan-1-amine	other-chemicalthing
and	O
its	O
free	O
base	O
form	O
has	O
a	O
chemical	O
formula	O
of	O
C19H21NO	other-chemicalthing
with	O
a	O
molecular	O
weight	O
of	O
279.376	O
g/mol	O
.	O

Wright	person-scholar
had	O
open	O
heart	O
surgery	O
in	O
1983	O
,	O
spurring	O
an	O
interest	O
in	O
health	O
psychology	O
,	O
especially	O
in	O
the	O
relationship	O
between	O
Type	O
A	O
personality	O
and	O
cardiac	other-medical
rehabilitation	other-medical
.	O

Additionally	O
,	O
dosing	O
naltrexone	other-medical
after	O
recent	O
opioid	other-medical
use	O
could	O
lead	O
to	O
precipitated	other-medical
withdrawal	other-medical
.	O

In	O
the	O
UK	location-GPE
,	O
Gardasil	other-medical
replaced	O
Cervarix	other-medical
in	O
September	O
2012	O
for	O
reasons	O
unrelated	O
to	O
safety	O
.	O

Influvac	other-medical
is	O
a	O
subunit	O
vaccine	O
produced	O
and	O
marketed	O
by	O
Mylan	organization-company
.	O

Bevacizumab	other-medical
was	O
approved	O
in	O
the	O
United	location-GPE
States	location-GPE
in	O
February	O
2004	O
,	O
for	O
use	O
in	O
metastatic	O
colorectal	O
cancer	O
when	O
used	O
with	O
standard	O
chemotherapy	O
treatment	O
(	O
as	O
first-line	O
treatment	O
)	O
and	O
with	O
5-fluorouracil	other-medical
-based	O
therapy	O
for	O
second-line	O
metastatic	O
colorectal	O
cancer	O
.	O

Pentobarbital	other-medical
(	O
previously	O
known	O
as	O
pentobarbitone	other-medical
in	O
Britain	location-GPE
and	O
Australia	location-GPE
)	O
is	O
a	O
short-acting	O
barbiturate	O
typically	O
used	O
as	O
a	O
sedative	O
,	O
a	O
preanesthetic	O
,	O
and	O
to	O
control	O
convulsions	O
in	O
emergencies	O
.	O

Aspirin	other-medical
increases	O
prothrombin	other-biologything
time	O
and	O
can	O
result	O
in	O
post-operative	O
complications	O
,	O
such	O
as	O
excessive	O
bleeding	O
.	O

Carbapenem-resistant	other-medical
Enterobacteriaceae	other-medical
(	O
CRE	other-medical
)	O
have	O
been	O
defined	O
as	O
carbapenem	other-biologything
-nonsusceptible	O
and	O
extended-spectrum	other-biologything
cephalosporin-resistant	O
``	O
Escherichia	other-biologything
coli	other-biologything
,	O
Enterobacter	other-biologything
aerogenes	other-biologything
,	O
Enterobacter	other-biologything
cloacae	other-biologything
``	O
complex	O
,	O
``	O
Klebsiella	other-biologything
pneumoniae	other-biologything
``	O
,	O
or	O
``	O
Klebsiella	other-biologything
oxytoca	other-biologything
``	O
.	O

For	O
the	O
treatment	O
of	O
yeast	O
keratitis	O
,	O
``	O
topical	O
amphotericin	other-medical
B	other-medical
is	O
usually	O
the	O
first	O
choice	O
.	O
''	O

Severe	O
allergic	O
reactions	O
(	O
anaphalaxis	other-disease
)	O
may	O
require	O
treatment	O
with	O
an	O
epinephrine	other-medical
pen	other-medical
,	O
which	O
is	O
an	O
injection	O
device	O
designed	O
to	O
be	O
used	O
by	O
a	O
non-healthcare	O
professional	O
when	O
emergency	O
treatment	O
is	O
warranted	O
.	O

Adderall	other-medical
is	O
a	O
drug	O
that	O
affects	O
the	O
central	other-biologything
nervous	other-biologything
system	other-biologything
and	O
is	O
prescribed	O
to	O
individuals	O
with	O
attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
and/or	O
narcolepsy	other-disease
.	O

Some	O
of	O
the	O
newer	O
psychiatric	O
medications	O
,	O
such	O
as	O
Zyprexa	other-medical
(	O
Olanzapine	other-medical
)	O
and	O
Cymbalta	other-medical
(	O
Duloxetine	other-medical
)	O
,	O
can	O
also	O
cause	O
significant	O
hyperglycemia	O
.	O

In	O
November	O
2009	O
,	O
Mencia	person-actor
began	O
appearing	O
in	O
commercials	O
for	O
a	O
weight-loss	O
product	O
called	O
Belly	other-medical
Burner	other-medical
,	O
which	O
he	O
has	O
claimed	O
to	O
have	O
used	O
personally	O
.	O

Use	O
is	O
widespread	O
among	O
amphetamine	other-medical
users	O
,	O
with	O
those	O
that	O
use	O
amphetamines	other-medical
and	O
benzodiazepines	other-medical
having	O
greater	O
levels	O
of	O
mental	O
health	O
problems	O
and	O
social	O
deterioration	O
.	O

These	O
treatments	O
were	O
finally	O
rendered	O
obsolete	O
by	O
the	O
discovery	O
of	O
penicillin	other-medical
,	O
and	O
its	O
widespread	O
manufacture	O
after	O
World	event-attack,battle,war,militaryconflict
War	event-attack,battle,war,militaryconflict
II	event-attack,battle,war,militaryconflict
allowed	O
syphilis	other-disease
to	O
be	O
effectively	O
and	O
reliably	O
cured	O
.	O

Recently	O
,	O
analeptics	O
have	O
been	O
turned	O
to	O
the	O
treatment	O
of	O
ADHD	other-disease
due	O
to	O
more	O
efficient	O
ways	O
to	O
treat	O
barbiturate	other-medical
overdoses	O
.	O

Doxorubicin	other-medical
is	O
loaded	O
into	O
the	O
liposomes	O
just	O
before	O
administration	O
to	O
patients	O
with	O
a	O
maximum	O
single	O
dose	O
of	O
75	O
mg/m2	O
every	O
3	O
weeks	O
.	O

Miglustat	other-medical
is	O
indicated	O
to	O
treat	O
adults	O
with	O
mild	O
to	O
moderate	O
type	O
I	O
Gaucher	other-disease
disease	O
for	O
whom	O
enzyme	O
replacement	O
therapy	O
is	O
unsuitable	O
.	O

The	O
condition	O
can	O
be	O
prevented	O
by	O
using	O
chloramphenicol	other-medical
at	O
the	O
recommended	O
doses	O
and	O
monitoring	O
blood	O
levels	O
,	O
or	O
alternatively	O
,	O
third	O
generation	O
cephalosporins	other-medical
can	O
be	O
effectively	O
substituted	O
for	O
the	O
drug	O
,	O
without	O
the	O
associated	O
toxicity	O
.	O

Another	O
potentially	O
serious	O
complication	O
associated	O
with	O
heparin	other-medical
use	O
is	O
called	O
heparin-induced	other-disease
thrombocytopenia	other-disease
(	O
HIT	other-disease
)	O
.	O

Polythiazide	other-medical
is	O
a	O
thiazide	other-medical
diuretic	other-medical
.	O

Many	O
users	O
of	O
dissociatives	O
have	O
been	O
concerned	O
about	O
the	O
possibility	O
of	O
NMDA	other-medical
antagonist	other-medical
neurotoxicity	other-medical
(	O
NAN	other-medical
)	O
.	O

The	O
KRAS	other-biologything
gene	O
encodes	O
a	O
small	O
G	other-biologything
protein	other-biologything
on	O
the	O
EGFR	other-medical
pathway	O
.	O

It	O
was	O
used	O
to	O
treat	O
symptoms	O
associated	O
with	O
allergies	O
and	O
colds	O
such	O
as	O
itchy	other-medical
and	other-medical
watery	other-medical
eyes	other-medical
,	O
runny	other-medical
nose	other-medical
,	O
nasal	other-medical
and	other-medical
sinus	other-medical
congestion	other-medical
,	O
and	O
sneezing	other-medical
.	O

Its	O
plasma	O
half-life	O
is	O
about	O
30	O
hours	O
when	O
it	O
is	O
given	O
as	O
single	O
dose	O
,	O
but	O
it	O
is	O
a	O
strong	O
inducer	other-medical
of	other-medical
hepatic	other-medical
enzymes	other-medical
and	O
the	O
plasma	O
half-life	O
shortens	O
to	O
about	O
15	O
hours	O
when	O
it	O
is	O
given	O
repeatedly	O
.	O

Piracetam	other-medical
is	O
not	O
permitted	O
in	O
compounded	O
drugs	O
or	O
dietary	O
supplements	O
in	O
the	O
United	O
States	O
.	O

The	O
rate	O
of	O
hypothyroidism	other-disease
is	O
around	O
six	O
times	O
higher	O
in	O
people	O
who	O
take	O
lithium	other-medical
.	O

The	O
biggest	O
controversy	O
of	O
the	O
2012	event-sportsevent
Breeders	event-sportsevent
'	event-sportsevent
Cup	event-sportsevent
related	O
to	O
the	O
use	O
of	O
the	O
anti-bleeding	O
medication	O
Furosemide	other-medical
(	O
Lasix	other-medical
)	O
,	O
commonly	O
used	O
in	O
North	location-GPE
America	location-GPE
but	O
not	O
permitted	O
elsewhere	O
.	O

This	O
was	O
considered	O
an	O
acceptable	O
risk	O
because	O
the	O
malaria	other-disease
could	O
later	O
be	O
treated	O
with	O
quinine	other-medical
,	O
which	O
was	O
available	O
at	O
that	O
time	O
.	O

Doxepin	other-medical
is	O
a	O
tertiary	O
amine	O
TCA	other-medical
,	O
with	O
its	O
side	O
chain-demethylated	O
metabolite	other-chemicalthing
nordoxepin	other-chemicalthing
being	O
a	O
secondary	O
amine	O
.	O

The	O
binding	O
affinity	O
(	O
K	O
)	O
and	O
inhibitory	O
potency	O
(	O
i.e.	O
,	O
the	O
half	O
maximal	O
inhibitory	O
concentration	O
or	O
IC	O
)	O
of	O
bupropion	other-medical
at	O
the	O
human	O
dopamine	other-biologything
transporter	O
are	O
526	O
nanomolar	O
(	O
nM	O
)	O
and	O
443	O
nM	O
,	O
respectively	O
.	O

Dermatologic	other-disease
conditions	other-disease
cause	O
about	O
75	O
%	O
of	O
cases	O
of	O
desquamative	other-disease
gingivitis	other-disease
,	O
and	O
over	O
95	O
%	O
of	O
the	O
dermatologic	other-disease
cases	other-disease
are	O
accounted	O
for	O
by	O
either	O
oral	other-medical
lichen	other-medical
planus	other-medical
or	O
cicatricial	other-medical
pemphigoid	other-medical
.	O

In	O
general	O
,	O
cytotoxic	other-medical
chemotherapy	other-medical
for	O
ALL	other-disease
combines	O
multiple	O
antileukemic	other-medical
drugs	O
tailored	O
to	O
each	O
person	O
.	O

Methylene	other-medical
blue	other-medical
is	O
also	O
used	O
as	O
a	O
dye	O
in	O
chromoendoscopy	O
,	O
and	O
is	O
sprayed	O
onto	O
the	O
mucosa	O
of	O
the	O
gastrointestinal	O
tract	O
in	O
order	O
to	O
identify	O
dysplasia	O
,	O
or	O
pre-cancerous	O
lesions	O
.	O

There	O
is	O
not	O
good	O
evidence	O
that	O
it	O
works	O
better	O
than	O
other	O
PPIs	other-medical
.	O

Contrary	O
to	O
most	O
other	O
injector	O
pens	O
,	O
epinephrine	other-medical
injector	O
pens	O
are	O
designed	O
to	O
administer	O
the	O
medication	O
via	O
intramuscular	O
injection	O
.	O

Flatulence	other-medical
has	O
been	O
recorded	O
in	O
whales	other-livingthing
.	O

Established	O
diagnoses	O
include	O
Down	other-medical
syndrome	other-medical
,	O
Fragile	other-medical
X	other-medical
syndrome	other-medical
,	O
Trisomy	other-medical
8	other-medical
mosaic	other-medical
syndrome	other-medical
,	O
Trisomy	other-medical
13	other-medical
syndrome	other-medical
,	O
Williams	other-medical
syndrome	other-medical
,	O
Angelman	other-medical
syndrome	other-medical
,	O
Smith–Magenis	other-medical
syndrome	other-medical
,	O
PKU	other-medical
,	O
Tuberous	other-medical
sclerosis	other-medical
,	O
Neurofibromatosis	other-medical
,	O
Sturge–Weber	other-medical
syndrome	other-medical
,	O
Congenital	other-medical
rubella	other-medical
syndrome	other-medical
,	O
the	O
syndrome	O
of	O
hypoxic	other-medical
/	O
ischemic	other-medical
perinatal	other-medical
brain	other-medical
injury	other-medical
,	O
lead	other-medical
encephalopathy	other-medical
,	O
hydrocephalus	other-medical
,	O
prosencephaly	other-medical
,	O
schizencephaly	other-medical
,	O
and	O
other	O
diagnoses	O
.	O

Combined	O
use	O
of	O
clonazepam	other-medical
with	O
certain	O
antidepressants	O
,	O
anticonvulsants	O
(	O
such	O
as	O
phenobarbital	other-medical
,	O
phenytoin	other-medical
,	O
and	O
carbamazepine	other-medical
)	O
,	O
sedative	O
antihistamines	O
,	O
opiates	O
,	O
and	O
antipsychotics	O
,	O
nonbenzodiazepines	O
(	O
such	O
as	O
zolpidem	other-medical
)	O
,	O
and	O
alcohol	O
may	O
result	O
in	O
enhanced	O
sedative	O
effects	O
.	O

Recommended	O
antibiotics	O
in	O
those	O
who	O
are	O
young	O
and	O
sexually	O
active	O
are	O
ceftriaxone	other-medical
and	O
doxycycline	other-medical
.	O

Air	O
under	O
moderately	O
high	O
pressure	O
,	O
such	O
as	O
is	O
used	O
when	O
diving	O
below	O
about	O
,	O
has	O
an	O
increasing	O
narcotic	other-medical
effect	O
on	O
the	O
nervous	O
system	O
.	O

Chloral	other-medical
hydrate	other-medical
has	O
not	O
been	O
approved	O
by	O
the	O
FDA	organization-other
in	O
the	O
United	location-GPE
States	location-GPE
or	O
the	O
EMA	organization-other
in	O
the	O
European	organization-government,governmentagency
Union	organization-government,governmentagency
for	O
any	O
medical	O
indication	O
and	O
is	O
on	O
the	O
FDA	organization-other
list	O
of	O
unapproved	O
drugs	O
that	O
are	O
still	O
prescribed	O
by	O
clinicians	O
.	O

Cervarix	other-medical
had	O
been	O
used	O
routinely	O
in	O
young	O
females	O
from	O
its	O
introduction	O
in	O
2008	O
,	O
but	O
was	O
only	O
effective	O
against	O
the	O
high-risk	O
HPV	other-disease
types	other-disease
16	other-disease
and	O
18	other-disease
,	O
neither	O
of	O
which	O
typically	O
causes	O
warts	O
.	O

Palliative	other-medical
care	other-medical
should	O
be	O
involved	O
earlier	O
,	O
rather	O
than	O
later	O
in	O
the	O
disease	O
course	O
.	O

More	O
severe	O
eruptions	O
usually	O
clear	O
up	O
after	O
treatment	O
for	O
one	O
to	O
three	O
months	O
with	O
Accutane	other-medical
or	O
tetracycline	other-medical
.	O

Most	O
MDMA	other-medical
production	O
in	O
China	location-GPE
is	O
for	O
domestic	O
consumption	O
.	O

In	O
2019	O
an	O
AAV9	other-medical
therapy	other-medical
was	O
approved	O
:	O
Onasemnogene	other-medical
abeparvovec	other-medical
.	O

Neuraminidase	other-medical
inhibitors	other-medical
(	O
NAIs	other-medical
)	O
are	O
a	O
class	O
of	O
drugs	O
which	O
block	O
the	O
neuraminidase	O
enzyme	O
.	O

in	O
2008	O
16	O
Anadin	other-medical
Paracetamol	other-medical
tablets	other-medical
each	O
containing	O
500	O
mg	O
of	O
paracetamol	O
cost	O
around	O
£2.09	other-currency
while	O
non-branded	O
equivalents	O
retailed	O
for	O
around	O
£0.35	other-currency
)	O
.	O

This	O
is	O
much	O
more	O
invasive	O
than	O
angioplasty	other-medical
.	O

As	O
several	O
HBS	organization-other
case	O
studies	O
point	O
out	O
,	O
Tylenol	other-medical
was	O
the	O
country	O
's	O
best-selling	O
over-the-counter	O
pain	O
reliever	O
at	O
the	O
time	O
of	O
the	O
poisonings	O
,	O
with	O
35	O
percent	O
of	O
the	O
market-more	O
than	O
the	O
next	O
three	O
brands	O
combined	O
.	O

It	O
fully	O
substitutes	O
for	O
MBDB	other-medical
but	O
not	O
amphetamine	other-medical
in	O
trained	O
animals	O
,	O
though	O
it	O
does	O
produce	O
disruption	O
for	O
the	O
latter	O
at	O
high	O
doses	O
.	O

There	O
is	O
tentative	O
evidence	O
of	O
benefit	O
for	O
tranexamic	other-medical
acid	other-medical
which	O
inhibits	O
clot	O
breakdown	O
.	O

Relative	O
to	O
other	O
SNRIs	other-medical
,	O
levomilnacipran	other-medical
,	O
as	O
well	O
as	O
milnacipran	other-medical
,	O
differ	O
in	O
that	O
they	O
are	O
much	O
more	O
balanced	O
reuptake	O
inhibitors	O
of	O
serotonin	O
and	O
norepinephrine	O
.	O

Iobenguane	other-medical
I	other-medical
131	other-medical
,	O
marketed	O
under	O
the	O
trade	O
name	O
Azedra	other-medical
,	O
has	O
had	O
a	O
clinical	O
trial	O
as	O
a	O
treatment	O
for	O
malignant	O
,	O
recurrent	O
or	O
unresectable	O
pheochromocytoma	other-disease
and	O
paraganglioma	other-disease
,	O
and	O
the	O
FDA	organization-other
approved	O
it	O
on	O
July	O
30	O
,	O
2018	O
.	O

The	O
main	O
interest	O
in	O
Ro15-4513	other-medical
was	O
as	O
an	O
antidote	O
to	O
alcohol	O
.	O

There	O
are	O
also	O
nootropic	O
drugs	O
such	O
as	O
the	O
common	O
racetams	other-medical
Piracetam	other-medical
and	O
Noopept	other-medical
(	O
O	O
mberaceta	other-medical
m	O
)	O
along	O
with	O
the	O
neuroprotective	O
Semax	other-chemicalthing
,	O
and	O
N-Acetyl	other-chemicalthing
Semax	other-chemicalthing
.	O

The	O
precise	O
mechanism	O
of	O
action	O
of	O
niacin	other-medical
therapeutic	other-medical
effects	O
has	O
not	O
been	O
fully	O
elucidated	O
,	O
but	O
appears	O
to	O
work	O
in	O
part	O
through	O
activation	O
of	O
HCA2	other-biologything
which	O
reduces	O
the	O
levels	O
of	O
intracellular	O
cAMP	other-medical
thereby	other-medical
inhibiting	O
lipolysis	O
in	O
adipocytes	other-biologything
.	O

However	O
,	O
Tim	person-athlete
admitted	O
to	O
using	O
the	O
prescription	O
drug	O
Adderall	other-medical
five	O
days	O
prior	O
to	O
the	O
event	O
;	O
Adderall	other-medical
is	O
a	O
drug	O
banned	O
by	O
the	O
Nevada	organization-other
State	organization-other
Athletic	organization-other
Commission	organization-other
.	O

Large	O
volume	O
pumps	other-chemicalthing
can	O
pump	O
fluid	O
replacement	O
such	O
as	O
saline	other-chemicalthing
solution	other-chemicalthing
,	O
medications	O
such	O
as	O
antibiotics	other-medical
or	O
nutrient	other-medical
solutions	other-medical
large	O
enough	O
to	O
feed	O
a	O
patient	O
.	O

Methyltestosterone	other-biologything
,	O
one	O
of	O
the	O
first	O
synthetic	O
AAS	other-medical
and	O
orally	O
active	O
androgens	O
,	O
was	O
introduced	O
in	O
1935	O
,	O
but	O
was	O
associated	O
with	O
hepatotoxicity	O
and	O
eventually	O
became	O
largely	O
medically	O
obsolete	O
.	O

It	O
has	O
been	O
known	O
since	O
the	O
1980s	O
that	O
buprenorphine	other-medical
binds	O
to	O
at	O
high	O
affinity	O
and	O
antagonizes	O
the	O
KOR	other-medical
.	O

Desipramine	other-medical
has	O
the	O
weakest	O
antihistamine	O
and	O
anticholinergic	O
effects	O
of	O
the	O
TCAs	other-medical
.	O

This	O
drug	O
is	O
commonly	O
misused	O
by	O
college	O
students	O
as	O
a	O
``	O
study	O
drug	O
,	O
''	O
although	O
research	O
suggests	O
that	O
stimulants	other-medical
are	O
more	O
efficient	O
at	O
correcting	O
shortfalls	O
than	O
enhancing	O
performance	O
.	O

Epinephrine	other-medical
is	O
the	O
drug	O
of	O
choice	O
for	O
treating	O
anaphylaxis	O
.	O

Cyclophosphamide	other-medical
is	O
one	O
of	O
the	O
most	O
potent	O
immunosuppressive	O
substances	O
.	O

Hyoscine	other-medical
butylbromide	other-medical
,	O
also	O
known	O
as	O
scopolamine	other-medical
butylbromide	other-medical
and	O
sold	O
under	O
the	O
brandname	organization-company
Buscopan	organization-company
among	O
others	O
,	O
is	O
an	O
anticholinergic	O
medication	O
used	O
to	O
treat	O
crampy	other-disease
abdominal	other-disease
pain	other-disease
,	O
esophageal	other-disease
spasms	other-disease
,	O
renal	other-disease
colic	other-disease
,	O
and	O
bladder	other-disease
spasms	other-disease
.	O

Thus	O
,	O
a	O
depressed	O
alpha	O
angle	O
could	O
be	O
treated	O
with	O
cryoprecipitate	other-medical
.	O

Desquamation	other-medical
(	O
skin	O
peeling	O
)	O
can	O
occur	O
with	O
severe	O
mercury	other-chemicalthing
poisoning	O
acquired	O
by	O
handling	O
elemental	O
mercury	other-chemicalthing
.	O

Vigabatrin	other-medical
is	O
a	O
drug	O
that	O
is	O
irreparably	O
suppresses	O
GABA	other-biologything
transaminase	other-biologything
that	O
causes	O
increased	O
amount	O
of	O
GABA	other-biologything
in	O
the	O
brain	O
.	O

Even	O
patients	O
desensitized	O
to	O
aspirin	other-medical
may	O
continue	O
to	O
need	O
other	O
medications	O
including	O
nasal	other-medical
steroids	other-medical
,	O
inhaled	other-medical
steroids	other-medical
,	O
and	O
leukotriene	other-medical
antagonists	other-medical
.	O

Creatine	other-medical
is	O
a	O
mass-produced	O
fitness	O
supplement	O
that	O
is	O
supposed	O
to	O
increase	O
the	O
user	O
's	O
muscle	O
mass	O
,	O
strength	O
and	O
power	O
.	O

This	O
can	O
be	O
done	O
through	O
a	O
CT	other-medical
or	O
MRI	other-medical
or	O
the	O
brain	O
;	O
these	O
are	O
the	O
first	O
imaging	O
modality	O
of	O
choice	O
.	O

The	O
term	O
``	O
gender	other-medical
identity	other-medical
disorder	other-medical
``	O
itself	O
introduced	O
in	O
DSM-III	art-writtenart
was	O
taken	O
from	O
Green	person-scholar
's	O
1974	O
work	O
.	O
Sexual	art-writtenart
Identity	art-writtenart
Conflict	art-writtenart
in	art-writtenart
Children	art-writtenart
and	art-writtenart
Adults	art-writtenart
.	O

Therefore	O
,	O
it	O
is	O
recommended	O
that	O
users	O
seeking	O
to	O
discontinue	O
an	O
SNRI	other-medical
slowly	O
taper	O
the	O
dose	O
under	O
the	O
supervision	O
of	O
a	O
professional	O
.	O

Radiation	other-medical
therapy	other-medical
is	O
generally	O
used	O
for	O
people	O
whose	O
tumors	O
are	O
not	O
completely	O
removed	O
by	O
surgery	O
,	O
for	O
people	O
who	O
are	O
not	O
good	O
candidates	O
for	O
surgery	O
because	O
of	O
other	O
health	O
problems	O
,	O
and	O
for	O
people	O
who	O
do	O
not	O
respond	O
adequately	O
to	O
surgery	O
and	O
medication	O
.	O

Using	O
caffeine	other-medical
and	O
naps	O
before	O
night	O
shifts	O
can	O
decrease	O
sleepiness	O
.	O

West	person-artist,author
mentions	O
the	O
antidepressant	O
drug	O
Lexapro	other-medical
in	O
reference	O
to	O
his	O
issues	O
with	O
mental	O
health	O
,	O
a	O
subject	O
West	person-artist,author
mostly	O
touched	O
on	O
in	O
the	O
song	O
``	O
I	art-music
Feel	art-music
Like	art-music
That	art-music
``	O
from	O
the	O
end	O
of	O
his	O
and	O
Steve	person-artist,author
McQueen	person-artist,author
's	O
music	O
video	O
for	O
West	person-artist,author
's	O
2015	O
single	O
``	O
All	art-music
Day	art-music
``	O
.	O

Individuals	O
with	O
coexisting	other-disease
seizure	other-disease
disorder	other-disease
may	O
require	O
treatment	O
with	O
anticonvulsants	other-medical
.	O

This	O
same	O
amount	O
of	O
potassium	other-medical
chloride	other-medical
would	O
do	O
no	O
harm	O
if	O
taken	O
orally	O
and	O
not	O
injected	O
directly	O
into	O
the	O
blood	O
.	O

Other	O
major	O
estradiol	other-biologything
esters	other-biologything
that	O
are	O
or	O
have	O
been	O
used	O
in	O
medicine	O
include	O
estradiol	other-biologything
acetate	other-biologything
,	O
estradiol	other-biologything
cypionate	other-biologything
,	O
estradiol	other-biologything
dipropionate	other-biologything
,	O
estradiol	other-biologything
enantate	other-biologything
,	O
estradiol	other-biologything
undecylate	other-biologything
,	O
and	O
polyestradiol	other-biologything
phosphate	other-biologything
(	O
an	O
estrogen	other-biologything
ester	other-biologything
polymer	other-biologything
)	O
,	O
as	O
well	O
as	O
the	O
nitrogen	other-medical
mustard	other-medical
alkylating	other-medical
antineoplastic	other-medical
agent	other-medical
estramustine	other-medical
phosphate	other-medical
(	O
estradiol	other-chemicalthing
normustine	other-chemicalthing
phosphate	other-chemicalthing
)	O
.	O

Possible	O
side	O
effects	O
of	O
olanzapine	other-medical
/	O
fluoxetine	other-medical
include	O
all	O
those	O
of	O
the	O
two	O
component	O
drugs	O
:	O
olanzapine	other-medical
(	O
side	O
effects	O
)	O
and	O
fluoxetine	other-medical
(	O
side	O
effects	O
)	O
.	O

Hsp90	other-medical
inhibitors	other-medical
are	O
another	O
possible	O
treatment	O
for	O
autoimmunity	O
,	O
because	O
hsp90	other-medical
is	O
necessary	O
for	O
proper	O
folding	O
of	O
many	O
pro-inflammatory	O
proteins	O
(	O
components	O
of	O
PI3K	other-biologything
,	O
MAPK	other-biologything
and	O
NF-kB	other-biologything
cascades	O
)	O
.	O

KvLQT1	other-biologything
are	O
also	O
expressed	O
in	O
the	O
pancreas	O
,	O
and	O
KvLQT1	other-disease
Long	other-disease
QT	other-disease
syndrome	other-disease
patients	O
has	O
been	O
shown	O
to	O
have	O
hyperinsulinemic	other-disease
hypoglycaemia	other-disease
following	O
an	O
oral	other-medical
glucose	other-medical
load	O
.	O

Allergan	organization-company
,	O
the	O
manufacturer	O
of	O
Botox	other-medical
,	O
agreed	O
to	O
a	O
$	other-currency
600	O
million	O
settlement	O
to	O
resolve	O
all	O
civil	O
and	O
criminal	O
liability	O
surrounding	O
the	O
promotion	O
of	O
Botox	other-medical
for	O
treatment	O
of	O
chronic	O
migraines	O
before	O
FDA	organization-government,governmentagency
review	O
or	O
approval	O
of	O
the	O
drug	O
for	O
such	O
use	O
.	O

Vardenafil	other-medical
's	O
relatively	O
short	O
effective	O
time	O
is	O
comparable	O
to	O
but	O
somewhat	O
longer	O
than	O
sildenafil	other-medical
's	O
.	O

The	O
same	O
study	O
showed	O
taking	O
potassium	other-medical
supplements	other-medical
during	O
gossypol	other-medical
treatment	O
did	O
not	O
prevent	O
hypokalemia	other-disease
in	O
primates	O
.	O

A	O
single	O
intramuscular	O
injection	O
of	O
20	O
to	O
30	O
mg	O
estradiol	other-chemicalthing
undecylate	other-chemicalthing
has	O
been	O
found	O
to	O
inhibit	O
ovulation	O
when	O
used	O
as	O
an	O
estrogen	other-biologything
-only	O
injectable	other-medical
contraceptive	other-medical
in	O
premenopausal	O
women	O
for	O
1	O
to	O
3	O
months	O
(	O
mean	O
1.7	O
months	O
)	O
as	O
well	O
.	O

The	O
American	organization-other
Sleep	organization-other
Apnea	organization-other
Association	organization-other
(	O
ASAA	organization-other
)	O
is	O
a	O
non-profit	O
organization	O
founded	O
in	O
1990	O
by	O
persons	O
with	O
sleep	other-medical
apnea	other-medical
,	O
health	O
care	O
providers	O
and	O
researchers	O
.	O

ADEP	other-medical
antibiotics	other-medical
can	O
be	O
used	O
to	O
defeat	O
resistant	O
bacterial	O
infections	O
.	O

Other	O
tertiary	O
amine	O
TCAs	other-medical
include	O
amitriptyline	other-medical
,	O
imipramine	other-medical
,	O
clomipramine	other-medical
,	O
dosulepin	other-medical
(	O
dothiepin	other-medical
)	O
,	O
and	O
trimipramine	other-medical
.	O

Paramedics	O
responded	O
and	O
injected	O
the	O
turtle	O
with	O
Valium	other-medical
after	O
the	O
turtle	O
refused	O
to	O
let	O
go	O
of	O
the	O
woman	O
's	O
lip	O
.	O

In	O
2011	O
,	O
after	O
pressure	O
by	O
activist	O
organizations	O
,	O
the	O
manufacturers	O
of	O
pentobarbital	other-medical
and	O
sodium	other-medical
thiopental	other-medical
halted	O
the	O
supply	O
of	O
the	O
drugs	O
to	O
U.S	location-GPE
.	location-GPE
prisons	O
performing	O
lethal	O
injections	O
and	O
required	O
all	O
resellers	O
to	O
do	O
the	O
same	O
.	O

Chronic	O
use	O
of	O
benzodiazepines	other-medical
can	O
lead	O
to	O
the	O
development	O
of	O
tolerance	O
with	O
a	O
decrease	O
of	O
benzodiazepine	other-medical
binding	O
sites	O
.	O

Warfarin	other-medical
is	O
tasteless	O
and	O
colourless	O
,	O
and	O
produces	O
symptoms	O
similar	O
to	O
those	O
that	O
Stalin	person-politician
exhibited	O
.	O

Nodules	other-medical
that	O
grow	O
larger	O
or	O
produce	O
symptoms	O
may	O
eventually	O
need	O
medical	O
care	O
.	O

By	O
suppressing	O
the	O
production	O
of	O
melatonin	other-medical
over	O
the	O
course	O
of	O
the	O
night	O
rats	O
showed	O
increased	O
rates	O
of	O
tumors	other-disease
over	O
the	O
course	O
of	O
a	O
four-week	O
period	O
.	O

It	O
is	O
a	O
component	O
of	O
the	O
PCDAI	other-medical
(	O
Pediatric	other-disease
Crohn	other-disease
's	other-disease
Disease	other-disease
Activity	O
Index	O
)	O
,	O
an	O
index	O
for	O
assessment	O
of	O
the	O
severity	O
of	O
inflammatory	O
bowel	O
disease	O
in	O
children	O
.	O

In	O
the	O
late	O
2000s	O
,	O
reports	O
in	O
the	O
Israeli	location-GPE
media	O
claimed	O
that	O
injections	O
of	O
long-acting	O
contraceptive	O
Depo-Provera	other-medical
had	O
been	O
forced	O
on	O
hundreds	O
of	O
Ethiopian-Jewish	O
immigrants	O
both	O
in	O
transit	O
camps	O
in	O
Ethiopia	location-GPE
and	O
after	O
their	O
arrival	O
in	O
Israel	location-GPE
.	O

Methylprednisolon	other-medical
e	O
dosage	O
and	O
administration	O
for	O
these	O
diseases	O
is	O
highly	O
variable	O
due	O
to	O
varied	O
pathophysiology	O
between	O
the	O
diseases	O
and	O
within	O
patients	O
diagnosed	O
with	O
a	O
given	O
disease	O
.	O

Fame	O
was	O
gained	O
by	O
the	O
resident	O
of	O
the	O
house	O
,	O
doctor	O
Gurari	person-other
Fabian	person-other
Natanovich	person-other
who	O
treated	O
skin	O
and	O
internal	O
diseases	O
X-rays	other-medical
.	O

Other	O
blood	O
thinners	O
sometimes	O
used	O
in	O
this	O
setting	O
include	O
bivalirudin	other-medical
and	O
fondaparinux	other-medical
.	O

It	O
is	O
both	O
a	O
cranial	O
and	O
a	O
focal	O
dystonia	other-medical
.	O

In	O
the	O
United	location-GPE
States	location-GPE
,	O
piracetam	other-medical
is	O
not	O
approved	O
by	O
the	O
Food	organization-government,governmentagency
and	organization-government,governmentagency
Drug	organization-government,governmentagency
Administration	organization-government,governmentagency
.	O

Levels	O
of	O
anti-GM1	other-medical
antibodies	O
are	O
elevated	O
in	O
patients	O
with	O
various	O
forms	O
of	O
dementia	O
.	O

First-generation	O
antihistamines	other-medical
include	O
diphenhydramine	other-medical
(	O
Benadryl	other-medical
)	O
,	O
carbinoxamine	other-medical
(	O
Clistin	other-medical
)	O
,	O
clemastine	other-medical
(	O
Tavist	other-medical
)	O
,	O
chlorpheniramine	other-medical
(	O
Chlor-Trimeton	other-medical
)	O
,	O
and	O

Third-line	O
medications	O
include	O
phenytoin	other-medical
for	O
children	O
and	O
phenobarbital	other-medical
for	O
adults	O
.	O

The	O
major	O
active	O
forms	O
of	O
spironolactone	other-medical
include	O
7α-thiomethylspironolactone	other-chemicalthing
(	O
7α-TMS	other-chemicalthing
)	O
and	O
canrenone	other-chemicalthing
(	O
7α-desthioacetyl-δ6-spironolactone	other-chemicalthing
)	O
,	O
while	O
more	O
minor	O
metabolites	O
of	O
spironolactone	other-medical
include	O
7α-thiospironolactone	other-chemicalthing
(	O
7α-TS	other-chemicalthing
)	O
,	O
6β-hydroxy-7α-thiomethylspironolactone	other-chemicalthing
(	O
6β-OH-7α-TMS	other-chemicalthing
)	O
,	O
and	O
a	O
number	O
of	O
others	O
.	O

Ketazolam	other-medical
breaks	O
down	O
in	O
the	O
blood	O
to	O
diazepam	other-medical
which	O
breaks	O
down	O
to	O
demoxepam	other-medical
which	O
breaks	O
down	O
to	O
desmethyldiazepam	other-chemicalthing
.	O

Because	O
it	O
contains	O
pseudoephedrine	other-medical
,	O
its	O
purchase	O
in	O
the	O
United	location-GPE
States	location-GPE
was	O
severely	O
restricted	O
by	O
the	O
Combat	other-law
Methamphetamine	other-law
Epidemic	other-law
Act	other-law
of	other-law
2005	other-law
over	O
fears	O
that	O
any	O
product	O
containing	O
pseudoephedrine	other-medical
can	O
be	O
used	O
to	O
make	O
methamphetamine	other-medical
.	O

Nonoxynol-9	other-medical
is	O
the	O
primary	O
chemical	O
in	O
spermicides	O
to	O
inhibit	O
sperm	O
motility	O
.	O

A	O
beneficial	O
side	O
effect	O
of	O
tamoxifen	other-medical
is	O
that	O
it	O
prevents	O
bone	O
loss	O
by	O
acting	O
as	O
an	O
ER	O
agonist	O
(	O
i.e.	O
,	O
mimicking	O
the	O
effects	O
of	O
estrogen	O
)	O
in	O
this	O
cell	O
type	O
.	O

It	O
is	O
a	O
common	O
protecting	O
group	O
for	O
sugars	O
and	O
sugar	O
alcohols	O
,	O
a	O
simple	O
example	O
being	O
solketal	other-medical
.	O

Protease	other-medical
inhibitors	other-medical
can	O
cause	O
a	O
syndrome	O
of	O
lipodystrophy	other-disease
,	O
hyperlipidemia	other-disease
,	O
diabetes	other-disease
mellitus	other-disease
type	other-disease
2	other-disease
,	O
and	O
kidney	other-disease
stones	other-disease
.	O

Steroids	other-medical
and	O
anti-emetic	other-medical
agents	other-medical
may	O
decrease	O
the	O
incidence	O
of	O
PRS	other-disease
.	O

Clenbuterol	other-medical
is	O
a	O
sympathomimetic	O
amine	O
used	O
by	O
sufferers	O
of	O
breathing	other-disease
disorders	other-disease
as	O
a	O
decongestant	O
and	O
bronchodilator	O
.	O

The	O
Chinese	location-GPE
herbal	O
medicine	O
long-dan-xie-gan-tan	other-medical
(	O
LDGXT	other-medical
)	O
has	O
also	O
been	O
shown	O
to	O
have	O
a	O
similar	O
anti	O
inflammatory	O
effect	O
,	O
and	O
in	O
mild	O
cases	O
may	O
be	O
used	O
alone	O
to	O
relieve	O
symptoms	O
while	O
infection	O
resolves	O
itself	O
.	O

Muscle	other-medical
relaxants	other-medical
are	O
typically	O
used	O
for	O
and	O
are	O
helpful	O
with	O
acute	other-medical
post-traumatic	other-medical
TTH	other-medical
rather	O
than	O
ETTH	other-medical
.	O

Medical	O
management	O
of	O
miscarriage	O
and	O
medical	O
abortion	O
using	O
drugs	O
such	O
as	O
misoprostol	other-medical
and	O
mifepristone	other-medical
are	O
safe	O
,	O
non-invasive	O
and	O
potentially	O
less	O
expensive	O
alternatives	O
to	O
D	other-medical
&	other-medical
amp	other-medical
;	other-medical
C	other-medical
.	O

Percodan	other-medical
has	O
largely	O
been	O
replaced	O
by	O
Percocet	other-medical
(	O
which	O
is	O
oxycodone	other-medical
combined	O
with	O
paracetamol	other-medical
(	O
acetaminophen	other-medical
)	O
instead	O
of	O
Percodan	other-medical
's	O
aspirin	other-medical
)	O
and	O
other	O
oxycodone-containing	O
compounds	O
for	O
post-operative	O
pain	O
.	O

He	O
survived	O
the	O
initial	O
surgery	O
,	O
but	O
after	O
a-five-and-a-half-month	O
battle	O
with	O
cancer	other-medical
,	O
he	O
died	O
in	O
Los	location-GPE
Angeles	location-GPE
on	O
July	O
31	O
,	O
1980	O
,	O
and	O
is	O
interred	O
at	O
Mount	location-other
Sinai	location-other
Memorial	location-other
Park	location-other
Cemetery	location-other
,	O
a	O
Jewish	location-GPE
cemetery	O
in	O
Los	location-GPE
Angeles	location-GPE
.	O

Low	O
volume	O
hyponatremia	O
is	O
typically	O
treated	O
with	O
intravenous	O
normal	other-medical
saline	other-medical
.	O

It	O
is	O
also	O
available	O
in	O
combination	O
with	O
pseudoephedrine	other-medical
,	O
a	O
decongestant	other-medical
,	O
known	O
as	O
loratadine	other-medical
/	O
pseudoephedrine	other-medical
.	O

Adam	person-scholar
Dicker	person-scholar
,	O
an	O
associate	O
professor	O
at	O
Jefferson	organization-education
Medical	organization-education
College	organization-education
of	organization-education
Thomas	organization-education
Jefferson	organization-education
University	organization-education
in	O
Philadelphia	location-GPE
,	O
supports	O
that	O
chemotherapy	other-medical
is	O
often	O
used	O
in	O
the	O
highest	O
possible	O
doses	O
.	O

Oral	other-medical
iron	other-medical
tablets	other-medical
are	O
not	O
easily	O
tolerated	O
and	O
may	O
cause	O
nausea	O
,	O
vomiting	O
,	O
abdominal	other-disease
pain	other-disease
,	O
constipation	other-disease
and	O
diarrhoea	other-disease
.	O

Haloperidol	other-medical
is	O
excreted	O
in	O
breast	O
milk	O
.	O

Brand	O
names	O
of	O
MPA	other-medical
in	O
combination	O
with	O
CEEs	other-medical
as	O
oral	O
tablets	O
in	O
different	O
countries	O
include	O
Prempro	other-medical
,	O
Premphase	other-medical
,	O
Premique	other-medical
,	O
Premia	other-medical
,	O
and	O
Premelle	other-medical
.	O

This	O
includes	O
epinephrine	other-medical
,	O
which	O
when	O
used	O
to	O
treat	O
anaphylaxis	other-disease
must	O
work	O
as	O
soon	O
as	O
possible	O
.	O

Ectrodactyly	other-disease
,	O
or	O
Split	other-disease
hand/split	other-disease
foot	other-disease
malformation	other-disease
(	O
SHFM	other-disease
)	O
type	O
1	O
is	O
the	O
only	O
form	O
of	O
split	O
hand/	O
malformation	O
associated	O
with	O
sensorineural	other-medical
hearing	other-medical
loss	other-medical
.	O

After	O
24	O
hours	O
,	O
a	O
severe	O
bleeding	O
disorder	O
ensues	O
,	O
leading	O
to	O
ecchymosis	other-medical
,	O
hematuria	other-medical
,	O
pulmonary	other-medical
,	O
and	O
intracranial	other-medical
hemorrhages	other-medical
,	O
and	O
acute	other-medical
kidney	other-medical
injury	other-medical
.	O

However	O
,	O
there	O
are	O
two	O
possible	O
causes	O
of	O
the	O
corneal	other-disease
inflammatory	other-disease
response	other-disease
:	O
an	O
infection	O
and/or	O
an	O
immunological	other-medical
response	other-medical
,	O
such	O
as	O
a	O
hypersensitivity	other-medical
type	other-medical
reaction	other-medical
,	O
or	O
(	O
rarely	O
)	O
Cogan	other-disease
syndrome	other-disease
.	O

Azerizin	other-medical
is	O
claimed	O
to	O
be	O
a	O
proprietary	O
blend	O
of	O
the	O
natural	O
ingredients	O
nicotinamide	other-chemicalthing
,	O
azelaic	other-chemicalthing
acid	other-chemicalthing
,	O
quercetin	other-chemicalthing
and	O
curcumin	other-chemicalthing
that	O
purportedly	O
combine	O
the	O
anti-inflammatory	O
and	O
antimicrobial	O
properties	O
,	O
along	O
with	O
inhibiting	O
effects	O
on	O
sebum	other-biologything
production	O
.	O

Side	O
effects	O
of	O
testosterone	other-medical
enanthate	other-medical
include	O
virilization	O
among	O
others	O
.	O

Ketoconazole	other-medical
has	O
activity	O
against	O
many	O
kinds	O
of	O
fungi	other-disease
that	O
may	O
cause	O
human	O
disease	O
,	O
such	O
as	O
``	O
Candida	other-disease
``	O
,	O
``	O
Histoplasma	other-disease
``	O
,	O
``	O
Coccidioides	other-disease
``	O
,	O
and	O
``	O
Blastomyces	other-disease
``	O
(	O
although	O
it	O
is	O
not	O
active	O
against	O
``	O
Aspergillus	other-disease
``	O
)	O
,	O
chromomycosis	other-disease
and	O
paracoccidioidomycosis	other-disease
.	O

Combretastatin	other-medical
and	O
pazopanib	other-medical
are	O
being	O
researched	O
in	O
combination	O
for	O
recurrent	O
ovarian	other-disease
cancer	other-disease
.	O

Formulations	O
containing	O
high	O
concentrations	O
of	O
aspirin	other-medical
often	O
smell	O
like	O
vinegar	O
because	O
aspirin	other-medical
can	O
decompose	O
through	O
hydrolysis	O
in	O
moist	O
conditions	O
,	O
yielding	O
salicylic	other-chemicalthing
and	O
acetic	other-chemicalthing
acids	other-chemicalthing
.	O

Hypoventilation	other-medical
exists	O
when	O
the	O
ratio	O
of	O
carbon	other-chemicalthing
dioxide	other-chemicalthing
production	O
to	O
alveolar	O
ventilation	O
increases	O
above	O
normal	O
values	O
–	O
greater	O
than	O
45mmHg	O
.	O

SERMs	other-medical
like	O
tamoxifen	other-medical
and	O
raloxifene	other-medical
can	O
also	O
be	O
considered	O
to	O
be	O
nonsteroidal	other-biologything
estrogens	other-biologything
in	O
some	O
tissues	O
.	O

The	O
analgesic	O
properties	O
of	O
the	O
plant	O
seem	O
to	O
be	O
related	O
to	O
its	O
effect	O
on	O
prostaglandin	other-medical
synthesis	other-medical
.	O

Cannabicyclohexanol	other-medical
is	O
not	O
listed	O
in	O
the	O
schedules	O
set	O
out	O
by	O
the	O
United	other-law
Nations	other-law
'	other-law
Single	other-law
Convention	other-law
on	other-law
Narcotic	other-law
Drugs	other-law
from	O
1961	O
nor	O
their	O
Convention	other-law
on	other-law
Psychotropic	other-law
Substances	other-law
from	O
1971	O
,	O
so	O
the	O
signatory	O
countries	O
to	O
these	O
international	O
drug	O
control	O
treaties	O
are	O
not	O
required	O
by	O
said	O
treaties	O
to	O
control	O
Cannabicyclohexanol	other-medical
.	O

Metoclopramide	other-medical
is	O
excreted	O
into	O
milk	O
.	O

Carbamazepine	other-medical
is	O
a	O
voltage-gated	O
sodium	O
channel	O
inhibitor	O
,	O
and	O
reduces	O
neuronal	O
excitability	O
by	O
preventing	O
depolarisation	O
.	O

Intermittent	other-medical
urinary	other-medical
catheterization	other-medical
is	O
used	O
to	O
relieve	O
the	O
bladder	O
in	O
people	O
with	O
urinary	other-disease
retention	other-disease
.	O

Colchicine	other-medical
in	O
combination	O
with	O
probenecid	other-medical
has	O
been	O
FDA	organization-government,governmentagency
-approved	O
prior	O
to	O
1982	O
.	O

For	O
his	O
suggestions	O
on	O
the	O
cure	O
of	O
varicocele	other-disease
and	O
on	O
the	O
operation	O
of	O
urethroplasty	other-medical
he	O
received	O
in	O
1842	O
one	O
of	O
the	O
Montyon	other-award
prizes	O
.	O

Ritonavir	other-medical
is	O
manufactured	O
as	O
Norvir	other-medical
by	O
AbbVie	organization-company
,	organization-company
Inc	organization-company
..	O

This	O
process	O
created	O
a	O
variety	O
with	O
less	O
tetrahydrocannabinol	other-chemicalthing
(	O
THC	other-chemicalthing
)	O
and	O
more	O
cannabidiol	other-chemicalthing
(	O
CBD	other-chemicalthing
)	O
than	O
typical	O
varieties	O
of	O
marijuana	other-medical
.	O

CPA	other-medical
is	O
used	O
as	O
an	O
antiandrogen	O
to	O
treat	O
high	O
androgen	O
levels	O
and	O
associated	O
symptoms	O
such	O
as	O
masculinization	O
due	O
to	O
conditions	O
like	O
polycystic	other-disease
ovary	other-disease
syndrome	other-disease
(	O
PCOS	other-disease
)	O
and	O
congenital	other-disease
adrenal	other-disease
hyperplasia	other-disease
(	O
CAH	other-disease
)	O
in	O
women	O
.	O

Abemaciclib	other-medical
(	O
LY2835219	other-medical
)	O
(	O
trade	O
name	O
Verzenio	other-medical
)	O
acts	O
as	O
a	O
selective	O
inhibitor	O
for	O
CDK4	other-biologything
and	O
CDK6	other-biologything
.	O

Deforolimus	other-medical
(	O
Ridaforolimus	other-medical
)	O
has	O
C43	O
secondary	O
alcohol	O
moiety	O
of	O
the	O
cyclohexyl	other-chemicalthing
group	O
of	O
Rapamycin	other-medical
that	O
was	O
substituted	O
with	O
phosphonate	other-chemicalthing
and	O
phosphinate	other-chemicalthing
groups	O
,	O
preventing	O
the	O
high-affinity	O
binding	O
to	O
mTOR	other-biologything
and	O
FKBP	other-biologything
.	O

IVF	other-medical
is	O
available	O
for	O
women	O
aged	O
18	O
to	O
45	O
.	O

He	O
is	O
also	O
credited	O
with	O
discovering	O
and	O
publishing	O
the	O
physiological	O
effects	O
of	O
amphetamine	other-medical
and	O
methylenedioxyamphetamine	other-medical
(	O
MDA	other-medical
)	O
.	O

It	O
,	O
along	O
with	O
WF-23	other-medical
the	O
other	O
``	O
2-naphthyl	other-medical
``	O
cocaine	other-medical
analogue	O
,	O
are	O
considered	O
the	O
more	O
potent	O
of	O
the	O
WF	other-medical
series	O
cocaine	other-medical
analogues	O
.	O

Pertaining	O
to	O
the	O
(	O
online	O
)	O
drug	O
market/trade	O
which	O
exists	O
in	O
Cambodia	location-GPE
,	O
more	O
recently	O
the	O
trade	O
took	O
on	O
its	O
international	O
intervention	O
in	O
which	O
officials	O
were	O
able	O
to	O
prevent	O
10,000	O
tablets	O
of	O
Codeine	other-medical
and	O
Valium	other-medical
being	O
sent	O
out	O
of	O
Cambodia	location-GPE
to	O
the	O
United	location-GPE
States	location-GPE
and	O
United	location-GPE
Kingdom	location-GPE
.	O

One	O
study	O
found	O
approximately	O
15	O
%	O
of	O
chronic	O
MDMA	O
users	O
met	O
the	O
DSM-IV	other-medical
diagnostic	O
criteria	O
for	O
substance	O
dependence	O
.	O

Signs	O
and	O
symptoms	O
of	O
withdrawal	O
from	O
abrupt	O
cessation	O
of	O
an	O
SNRI	other-medical
include	O
dizziness	O
,	O
anxiety	O
,	O
insomnia	O
,	O
nausea	O
,	O
sweating	O
,	O
and	O
flu-like	O
symptoms	O
,	O
such	O
as	O
lethargy	O
and	O
malaise	O
.	O

It	O
has	O
a	O
reasonably	O
fast	O
rate	O
of	O
occupancy	O
of	O
dopamine	other-chemicalthing
transporters	O
in	O
the	O
brain	O
,	O
though	O
slower	O
than	O
that	O
of	O
cocaine	other-medical
itself	O
.	O

There	O
has	O
been	O
controversy	O
over	O
the	O
decision	O
by	O
NHS	organization-other
Greater	location-GPE
Glasgow	location-GPE
to	O
downgrade	O
facilities	O
at	O
the	O
local	O
Stobhill	building-hospital
Hospital	building-hospital
in	O
nearby	O
Springburn	location-GPE
to	O
an	O
Ambulatory	building-hospital
care	O
facility	O
,	O
which	O
will	O
result	O
in	O
the	O
nearest	O
Accident	building-hospital
and	building-hospital
Emergency	building-hospital
and	O
inpatient	O
facilities	O
being	O
located	O
at	O
the	O
Glasgow	building-hospital
Royal	building-hospital
Infirmary	building-hospital
in	O
the	O
city	O
centre	O
,	O
as	O
well	O
as	O
the	O
development	O
of	O
an	O
inpatient	O
Psychiatric	other-medical
hospital	O
at	O
the	O
site	O
.	O

He	O
and	O
his	O
colleagues	O
often	O
served	O
as	O
their	O
own	O
lab	O
rats	O
,	O
voluntarily	O
undergoing	O
such	O
procedures	O
as	O
self-induced	O
iron	other-medical
deficiency	other-medical
anemia	other-medical
,	O
sub-dermal	other-medical
bone	other-medical
transplantation	other-medical
,	O
and	O
consumption	O
of	O
radio-labeled	other-medical
iron	other-medical
.	O

Whereas	O
other	O
TCAs	other-medical
are	O
useful	O
for	O
treating	O
insomnia	O
,	O
desipramine	O
can	O
cause	O
insomnia	other-disease
as	O
a	O
side	O
effect	O
due	O
to	O
its	O
activating	O
properties	O
.	O

Varespladib	other-medical
treatment	O
exerted	O
a	O
significant	O
inhibitory	O
effect	O
on	O
snake	O
venom	O
PLA₂	other-biologything
both	O
``	O
in	O
vitro	O
''	O
and	O
in	O
``	O
vivo	O
''	O
.	O

One	O
NSAID	other-medical
in	O
particular	O
,	O
indomethacin	O
,	O
can	O
inhibit	O
new	O
collagen	O
deposition	O
,	O
thus	O
impairing	O
the	O
healing	O
process	O
for	O
the	O
infarcted	O
region	O
.	O

Pfizer	organization-company
UK	organization-company
was	O
presented	O
with	O
the	O
Queen	other-award
's	other-award
Award	other-award
for	other-award
Technological	other-award
Achievement	other-award
in	O
1979	O
,	O
in	O
recognition	O
of	O
the	O
outstanding	O
contribution	O
made	O
to	O
tropical	O
medicine	O
by	O
the	O
medicine	O
Mansil	other-medical
(	O
oxamniquine	O
)	O
,	O
which	O
had	O
been	O
developed	O
at	O
the	O
Sandwich	building-other
site	building-other
.	O

The	O
acute	O
administration	O
of	O
stimulants	O
such	O
as	O
amphetamines	other-medical
typically	O
produces	O
hyperglycemia	O
;	O
chronic	O
use	O
,	O
however	O
,	O
produces	O
hypoglycemia	O
.	O

Pharmacological	O
studies	O
point	O
to	O
alterations	O
in	O
dopamine	other-medical
function	O
and	O
the	O
endocannabinoid	other-medical
system	O
.	O

Multiple	O
studies	O
have	O
found	O
docusate	other-medical
to	O
be	O
no	O
more	O
effective	O
than	O
a	O
placebo	O
for	O
improving	O
constipation	O
.	O

Nelfinavir	other-medical
is	O
an	O
orally	O
bioavailable	O
human	O
immunodeficiency	O
virus	O
HIV-1	other-biologything
protease	O
inhibitor	O
(	O
Ki=2nM	O
)	O
and	O
is	O
widely	O
prescribed	O
in	O
combination	O
with	O
HIV	other-biologything
reverse	O
transcriptase	O
inhibitors	O
for	O
the	O
treatment	O
of	O
HIV	other-biologything
infection	O
.	O

It	O
may	O
also	O
cause	O
interactions	O
with	O
anesthetics	O
,	O
so	O
its	O
use	O
should	O
be	O
related	O
to	O
the	O
veterinarian	O
if	O
the	O
animal	O
is	O
going	O
into	O
surgery	O
,	O
and	O
it	O
decreases	O
the	O
kidneys	O
'	O
ability	O
to	O
excrete	O
aspirin	other-medical
,	O
so	O
dosages	O
will	O
need	O
to	O
be	O
adjusted	O
if	O
combined	O
with	O
that	O
drug	O
.	O

He	O
also	O
supported	O
the	O
idea	O
of	O
a	O
p24-	other-medical
vaccine	other-medical
without	O
gp120	other-medical
which	O
was	O
patented	O
by	O
Jonas	person-other
Salk	person-other
as	O
``	O
Remune	other-medical
``	O
.	O

In	O
insulin-dependent	other-disease
diabetic	other-disease
people	O
,	O
this	O
phenomenon	O
is	O
termed	O
hypoglycemia	other-medical
unawareness	O
,	O
and	O
is	O
a	O
significant	O
clinical	O
problem	O
when	O
improved	O
glycemic	O
control	O
is	O
attempted	O
.	O

For	O
people	O
who	O
have	O
already	O
had	O
a	O
single	O
DVT	other-disease
event	O
,	O
the	O
best	O
way	O
to	O
prevent	O
a	O
second	O
DVT	other-disease
is	O
appropriate	O
anticoagulation	other-medical
therapy	other-medical
.	O

After	O
residency	O
in	O
Pediatrics	other-medical
at	O
Hokkaido	building-hospital
University	building-hospital
Hospital	building-hospital
,	O
he	O
worked	O
as	O
a	O
pediatrician	other-medical
in	O
Japan	location-GPE
for	O
several	O
years	O
.	O

This	O
includes	O
methotrexate	other-medical
for	O
juvenile	other-disease
idiopathic	other-disease
arthritis	other-disease
and	O
sumatriptan	other-medical
for	O
treatment	O
of	O
migraines	other-disease
.	O

Type	other-disease
2	other-disease
diabetes	other-disease
is	O
a	O
progressive	O
condition	O
in	O
which	O
the	O
body	O
becomes	O
resistant	O
to	O
the	O
normal	O
effects	O
of	O
insulin	other-medical
and/or	O
gradually	O
loses	O
the	O
capacity	O
to	O
produce	O
enough	O
insulin	other-medical
in	O
the	O
pancreas	O
.	O

Although	O
gabapentin	other-medical
and	O
pregabalin	other-medical
possess	O
low	O
abuse	O
potential	O
,	O
these	O
drugs	O
can	O
cause	O
physical	O
dependence	O
over	O
the	O
course	O
of	O
normal	O
treatment	O
,	O
and	O
certain	O
patients	O
may	O
become	O
psychologically	O
dependent	O
as	O
well	O
.	O

Pentobarbital	other-medical
also	O
has	O
an	O
application	O
in	O
reducing	O
intracranial	O
pressure	O
in	O
Reye	other-disease
's	other-disease
syndrome	other-disease
,	O
traumatic	other-disease
brain	other-disease
injury	other-disease
and	O
induction	O
of	O
coma	O
in	O
cerebral	other-disease
ischemia	other-disease
patients	O
.	O

Pharmacologically	O
,	O
it	O
is	O
of	O
interest	O
as	O
an	O
acetylcholinesterase	other-medical
inhibitor	other-medical
and	O
accordingly	O
as	O
possibly	O
relevant	O
to	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
.	O

Individuals	O
with	O
hemodynamically	other-disease
``	other-disease
unstable	other-disease
''	other-disease
ventricular	other-disease
tachycardia	other-disease
``	O
should	O
not	O
''	O
initially	O
receive	O
amiodarone	other-medical
.	O

Tadalafil	other-medical
is	O
structurally	O
different	O
from	O
both	O
sildenafil	other-medical
and	O
vardenafil	other-medical
.	O

Peripheral	other-disease
edema	other-disease
(	O
fluid	O
accumulation	O
in	O
the	O
tissues	O
)	O
occurs	O
at	O
rate	O
of	O
10.8	O
%	O
at	O
a	O
10-mg	O
dose	O
(	O
versus	O
0.6	O
%	O
for	O
placebos	other-medical
)	O
,	O
and	O
is	O
three	O
times	O
more	O
likely	O
in	O
women	O
than	O
in	O
men	O
.	O

A	O
subsequent	O
double-blind	O
RCT	product-other
,	O
that	O
treated	O
patients	O
who	O
self-poisoned	O
,	O
found	O
no	O
benefit	O
of	O
pralidoxime	other-medical
,	O
including	O
specifically	O
in	O
chlorpyrifos	O
patients	O
.	O

Another	O
type	O
of	O
immunotherapy	O
involves	O
vaccines	O
,	O
including	O
TroVax	other-medical
.	O

Haloperidol	other-medical
is	O
also	O
used	O
on	O
many	O
different	O
kinds	O
of	O
animals	O
for	O
nonselective	O
tranquilization	O
and	O
diminishing	O
behavioral	O
arousal	O
,	O
in	O
veterinary	O
and	O
other	O
settings	O
including	O
captivity	O
management	O
.	O

A	O
stroke	other-disease
is	O
caused	O
by	O
hypoperfusion	O
(	O
lack	O
of	O
oxygen	O
)	O
to	O
an	O
area	O
of	O
the	O
brain	O
,	O
which	O
is	O
commonly	O
caused	O
by	O
thrombosis	other-medical
or	O
embolism	other-medical
.	O

Talley	person-scholar
's	person-scholar
research	O
interests	O
are	O
in	O
neurogastroenterology	other-medical
;	O
including	O
the	O
treatment	O
,	O
pathophysiology	O
and	O
epidemiology	O
of	O
functional	other-disease
dyspepsia	other-disease
and	O
irritable	other-disease
bowel	other-disease
syndrome	other-disease
;	O
he	O
is	O
considered	O
an	O
international	O
authority	O
in	O
the	O
field	O
.	O

The	O
effects	O
of	O
recreational	O
use	O
are	O
exhaustion	O
and	O
an	O
accumulation	O
of	O
“	O
sleep	O
debt.	O
”	O
Furthermore	O
,	O
frequent	O
use	O
of	O
adderall	other-medical
during	O
the	O
day	O
and	O
night	O
can	O
lead	O
to	O
sleep	O
deprivation	O
and	O
insomnia	other-disease
.	O

Rabeprazole	other-medical
binds	O
to	O
cysteine	other-chemicalthing
813	other-chemicalthing
and	O
both	O
892	other-chemicalthing
and	O
321	other-chemicalthing
.	O

CAR-302,196	other-medical
(	O
also	O
known	O
as	O
PCMG	other-medical
or	O
just	O
by	O
its	O
code	O
number	O
302196	other-medical
)	O
is	O
a	O
moderately	O
potent	O
and	O
relatively	O
short	O
lasting	O
anticholinergic	O
deliriant	O
drug	O
,	O
related	O
to	O
the	O
chemical	O
warfare	O
agent	O
3-	O
Quinuclidinyl	other-chemicalthing
benzilate	other-chemicalthing
(	O
QNB	other-chemicalthing
)	O
.	O

5-ARIs	other-medical
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
hirsutism	other-disease
in	O
women	O
.	O

Spirorenone	other-medical
possesses	O
5–8	O
times	O
the	O
antimineralocorticoid	O
activity	O
of	O
spironolactone	other-medical
in	O
animal	O
studies	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
if	O
combining	O
aspirin	other-medical
with	O
any	O
``	O
natural	O
''	O
supplements	O
with	O
COX-2-inhibiting	O
properties	O
,	O
such	O
as	O
garlic	other-chemicalthing
extracts	other-chemicalthing
,	O
curcumin	other-chemicalthing
,	O
bilberry	other-chemicalthing
,	O
pine	other-chemicalthing
bark	other-chemicalthing
,	O
ginkgo	other-chemicalthing
,	O
fish	other-chemicalthing
oil	other-chemicalthing
,	O
resveratrol	other-chemicalthing
,	O
genistein	other-chemicalthing
,	O
quercetin	other-chemicalthing
,	O
resorcinol	other-chemicalthing
,	O
and	O
others	O
.	O

Plantar	O
warts	O
are	O
not	O
prevented	O
by	O
inoculation	O
with	O
HPV	other-medical
vaccines	O
because	O
the	O
warts	O
are	O
caused	O
by	O
different	O
strains	O
of	O
HPV	other-medical
.	O

Research	O
continued	O
,	O
further	O
fueled	O
by	O
knowledge	O
gained	O
from	O
other	O
techniques	O
like	O
TMS	other-medical
and	O
fMRI	other-medical
.	O

All	O
PPIs	other-medical
react	O
with	O
cysteine	other-chemicalthing
813	other-chemicalthing
in	O
the	O
loop	O
between	O
TM5	other-chemicalthing
and	O
TM6	other-chemicalthing
on	O
the	O
H+	other-chemicalthing
/	O
K+	other-chemicalthing
ATPase	other-chemicalthing
,	O
fixing	O
the	O
enzyme	O
in	O
the	O
E2	O
configuration	O
.	O

Doxorubicin	other-medical
has	O
been	O
referred	O
to	O
frequently	O
as	O
a	O
highly-promising	O
anti-	O
cancer	other-disease
drug	O
that	O
is	O
also	O
being	O
utilized	O
in	O
chemotherapy	other-medical
treatments	O
;	O
however	O
,	O
as	O
with	O
nearly	O
all	O
chemotherapeutics	other-medical
,	O
the	O
issue	O
of	O
drug	O
resistance	O
remains	O
.	O

Naltrexone	other-medical
is	O
not	O
as	O
widely	O
used	O
as	O
buprenorphine	other-medical
or	O
methadone	other-medical
for	O
OUD	other-disease
due	O
to	O
low	O
rates	O
of	O
patient	O
acceptance	O
,	O
non-adherence	O
due	O
to	O
daily	O
dosing	O
,	O
and	O
difficulty	O
achieving	O
abstinence	O
from	O
opioids	other-medical
before	O
beginning	O
treatment	O
.	O

Of	O
the	O
344	O
wounded	O
that	O
were	O
admitted	O
to	O
the	O
Tripler	building-hospital
Army	building-hospital
Hospital	building-hospital
,	O
only	O
13	O
did	O
not	O
survive	O
,	O
and	O
it	O
is	O
unlikely	O
that	O
thiopentone	other-medical
overdose	O
was	O
responsible	O
for	O
more	O
than	O
a	O
few	O
of	O
these	O
.	O

Despite	O
the	O
non-steroidal	O
nature	O
of	O
finerenone	other-medical
which	O
yields	O
a	O
different	O
lipophilicity	other-medical
and	O
polarity	O
profile	O
for	O
this	O
compound	O
,	O
finerenone	other-medical
's	O
affinity	O
toward	O
mineralocorticoid	other-medical
receptors	O
is	O
equal	O
to	O
that	O
of	O
spironolactone	other-medical
and	O
500	O
times	O
that	O
of	O
eplerenone	other-medical
,	O
hinting	O
that	O
the	O
steroidal	O
core	O
component	O
of	O
most	O
antimineralocorticoids	O
is	O
not	O
essential	O
for	O
mineralocorticoid	other-medical
receptor	O
affinity	O
.	O

It	O
was	O
one	O
of	O
the	O
earlier	O
bacteria	O
in	O
which	O
penicillin	other-medical
resistance	O
was	O
found—in	O
1947	O
,	O
just	O
four	O
years	O
after	O
the	O
drug	O
started	O
being	O
mass-produced	O
.	O

Levomethorphan	other-medical
is	O
a	O
prodrug	O
to	O
levorphanol	other-medical
,	O
analogously	O
to	O
DXM	other-medical
acting	O
as	O
a	O
prodrug	O
to	O
dextrorphan	other-medical
or	O
codeine	O
behaving	O
as	O
a	O
prodrug	O
to	O
morphine	other-medical
.	O

Upon	O
his	O
return	O
in	O
1951	O
,	O
Crosby	person-scholar
established	O
both	O
the	O
hematology	other-medical
and	O
oncology	other-medical
specialties	O
at	O
Walter	building-hospital
Reed	building-hospital
Army	building-hospital
Hospital	building-hospital
a	O
position	O
he	O
would	O
hold	O
until	O
1965	O
.	O

Chlomethiazole	other-medical
appears	O
to	O
also	O
have	O
another	O
mechanism	O
of	O
action	O
mediating	O
some	O
of	O
its	O
hypothermic	O
and	O
neuroprotective	O
effects	O
.	O

Isavuconazonium	other-medical
comprises	O
an	O
``	O
N	O
''	O
-	O
(	O
3-acetoxypropyl	O
)	O
-	O
''	O
N	O
''	O
-methylamino-carboxymethyl	O
group	O
linked	O
through	O
an	O
ester	other-chemicalthing
moiety	other-chemicalthing
to	O
the	O
triazole	other-chemicalthing
nitrogen	other-chemicalthing
in	O
isavuconazole	other-chemicalthing
.	O

Pentobarbital	other-medical
-induced	O
coma	O
has	O
been	O
advocated	O
in	O
patients	O
with	O
acute	other-disease
liver	other-disease
failure	other-disease
refractory	O
to	O
mannitol	other-medical
.	O

Gemzar	other-medical
also	O
is	O
routinely	O
used	O
in	O
the	O
treatment	O
of	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
boxed	O
warning	O
about	O
heart	other-medical
attack	other-medical
was	O
removed	O
;	O
the	O
warning	O
about	O
heart	other-medical
failure	other-medical
remained	O
in	O
place	O
.	O

This	O
can	O
be	O
seen	O
in	O
people	O
who	O
are	O
experiencing	O
the	O
classic	O
signs	O
of	O
pericarditis	other-disease
but	O
then	O
show	O
signs	O
of	O
relief	O
,	O
and	O
progress	O
to	O
show	O
signs	O
of	O
cardiac	O
tamponade	O
which	O
include	O
decreased	O
alertness	O
and	O
lethargy	O
,	O
pulsus	O
paradoxus	O
(	O
decrease	O
of	O
at	O
least	O
10	O
mmHg	O
of	O
the	O
systolic	O
blood	O
pressure	O
upon	O
inspiration	O
)	O
,	O
low	O
blood	O
pressure	O
(	O
due	O
to	O
decreased	O
cardiac	O
index	O
)	O
,	O
(	O
jugular	O
vein	O
distention	O
from	O
right	O
sided	O
heart	O
failure	O
and	O
fluid	O
overload	O
)	O
,	O
distant	O
heart	O
sounds	O
on	O
auscultation	O
,	O
and	O
equilibration	O
of	O
all	O
the	O
diastolic	O
blood	O
pressures	O
on	O
cardiac	other-medical
catheterization	other-medical
due	O
to	O
the	O
constriction	O
of	O
the	O
pericardium	other-disease
by	O
the	O
fluid	O
.	O

Patients	O
should	O
therefore	O
always	O
be	O
screened	O
for	O
G6PD	other-biologything
deficiency	O
prior	O
to	O
being	O
prescribed	O
pamaquine	other-medical
.	O

Before	O
initiating	O
warfarin	other-medical
therapy	other-medical
,	O
a	O
few	O
days	O
of	O
therapeutic	other-medical
heparin	other-medical
may	O
be	O
administered	O
to	O
prevent	O
warfarin	other-disease
necrosis	other-disease
and	O
other	O
progressive	O
or	O
recurrent	O
thrombotic	O
complications	O
.	O

Because	O
borage	O
oil	O
can	O
theoretically	O
lower	O
the	O
seizure	O
threshold	O
due	O
to	O
its	O
GLA	other-chemicalthing
content	O
,	O
it	O
could	O
therefore	O
trigger	O
a	O
seizure	O
in	O
users	O
of	O
phenothiazines	other-medical
or	O
tricyclic	other-medical
antidepressants	other-medical
.	O

Unlike	O
α2	other-biologything
adrenoceptor	other-biologything
agonists	O
such	O
as	O
guanfacine	other-medical
and	O
clonidine	other-medical
,	O
atomoxetine	other-medical
's	O
use	O
can	O
be	O
abruptly	O
stopped	O
without	O
significant	O
discontinuation	O
effects	O
being	O
seen	O
.	O

A	O
large	O
cohort	O
study	O
in	O
Denmark	location-GPE
found	O
,	O
in	O
addition	O
,	O
no	O
association	O
between	O
metoclopramide	other-medical
exposure	O
and	O
miscarriage	O
.	O

The	O
Neuropsychiatric	other-medical
EEG-Based	other-medical
Assessment	other-medical
Aid	other-medical
(	O
NEBA	other-medical
)	O
System	O
a	O
device	O
used	O
to	O
measure	O
the	O
Theta-to-Beta	O
ratio	O
was	O
approved	O
as	O
a	O
tool	O
to	O
assist	O
in	O
diagnosis	O
of	O
ADHD	other-disease
on	O
July	O
15	O
,	O
2013	O
.	O

Sinus	O
node	O
blocker	O
Ivabradine	other-medical
can	O
successfully	O
restrain	O
heart	O
rate	O
in	O
POTS	other-disease
without	O
affecting	O
blood	O
pressure	O
,	O
demonstrated	O
in	O
approximately	O
60	O
%	O
of	O
people	O
with	O
POTS	other-disease
treated	O
in	O
an	O
open-label	O
trial	O
of	O
ivabradine	other-medical
experienced	O
symptom	O
improvement	O
.	O

Human	other-medical
PTRF	other-medical
mutations	other-medical
may	O
cause	O
secondary	other-disease
deficiency	other-disease
of	other-disease
caveolins	other-disease
,	O
resulting	O
in	O
generalized	O
lipodystrophy	other-medical
in	O
association	O
with	O
in	O
muscular	other-medical
dystrophy	other-medical
.	O

A	O
D	other-medical
&	other-medical
amp	other-medical
;	other-medical
C	other-medical
may	O
be	O
performed	O
early	O
in	O
pregnancy	O
to	O
remove	O
pregnancy	O
tissue	O
,	O
either	O
in	O
the	O
case	O
of	O
a	O
non-viable	O
pregnancy	O
,	O
such	O
as	O
a	O
missed	O
or	O
incomplete	O
miscarriage	O
,	O
or	O
an	O
undesired	O
pregnancy	O
,	O
as	O
in	O
a	O
surgical	O
abortion	O
.	O

The	O
U.S.	organization-other
Centers	organization-other
for	organization-other
Disease	organization-other
Control	organization-other
and	organization-other
Prevention	organization-other
recommends	O
the	O
use	O
of	O
oseltamivir	other-medical
(	O
Tamiflu	other-medical
)	O
or	O
zanamivir	other-medical
(	O
Relenza	other-medical
)	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
infection	O
with	O
swine	other-disease
influenza	other-disease
viruses	other-disease
;	O
however	O
,	O
the	O
majority	O
of	O
people	O
infected	O
with	O
the	O
virus	O
make	O
a	O
full	O
recovery	O
without	O
requiring	O
medical	O
attention	O
or	O
antiviral	O
drugs	O
.	O

Chronic	other-disease
kidney	other-disease
disease	other-disease
is	O
defined	O
as	O
prolonged	O
kidney	other-medical
abnormalities	other-medical
(	O
functional	O
and/or	O
structural	O
in	O
nature	O
)	O
that	O
last	O
for	O
more	O
than	O
three	O
weeks	O
.	O

Pilocarpine	other-medical
drops	other-medical
may	O
be	O
administered	O
as	O
a	O
treatment	O
as	O
well	O
as	O
a	O
diagnostic	O
measure	O
.	O

Tyrosine	other-biologything
kinases	other-biologything
play	O
a	O
particularly	O
important	O
role	O
in	O
cancer	O
,	O
and	O
several	O
agents	O
that	O
block	O
their	O
activity	O
are	O
now	O
used	O
as	O
anti-cancer	O
drugs	O
,	O
such	O
as	O
Imatinib	other-medical
or	O
Gleevec	other-medical
.	O

Botulinum	other-medical
toxin	other-medical
is	O
used	O
to	O
treat	O
a	O
number	O
of	O
therapeutic	O
indications	O
,	O
many	O
of	O
which	O
are	O
not	O
part	O
of	O
the	O
approved	O
drug	O
label	O
.	O

Clinical	O
trials	O
began	O
in	O
Europe	location-GPE
in	O
November	O
1998	O
for	O
the	O
MicroMed	other-medical
DeBakey	other-medical
VAD	other-medical
.	O

For	O
the	O
less	O
aggressive	O
allergic	other-disease
bronchopulmonary	other-disease
aspergillosis	other-disease
,	O
findings	O
suggest	O
the	O
use	O
of	O
oral	O
steroids	other-medical
for	O
a	O
prolonged	O
period	O
of	O
time	O
,	O
preferably	O
for	O
6–9	O
months	O
in	O
allergic	other-disease
aspergillosis	other-disease
of	O
the	O
lungs	O
.	O

It	O
was	O
developed	O
under	O
contract	O
to	O
Edgewood	organization-company
Arsenal	organization-company
during	O
the	O
1960s	O
as	O
part	O
of	O
the	O
US	location-GPE
military	O
chemical	O
weapons	O
program	O
,	O
during	O
research	O
to	O
improve	O
upon	O
the	O
properties	O
of	O
earlier	O
agents	O
such	O
as	O
QNB	other-medical
.	O

A	O
phase	O
three	O
clinical	O
trial	O
found	O
that	O
Ribocyclib	other-medical
administered	O
in	O
combination	O
with	O
letrozole	other-medical
increased	O
the	O
likelihood	O
of	O
progression	O
free	O
survival	O
to	O
63	O
%	O
in	O
the	O
first	O
18	O
months	O
of	O
therapy	O
versus	O
42	O
%	O
for	O
letrozole	other-medical
alone	O
.	O

The	O
first	O
hyaluronan	other-chemicalthing
biomedical	O
product	O
,	O
Healon	product-other
,	O
was	O
developed	O
in	O
the	O
1970s	O
and	O
1980s	O
by	O
Pharmacia	organization-company
,	O
and	O
approved	O
for	O
use	O
in	O
eye	O
surgery	O
(	O
i.e.	O
,	O
corneal	other-medical
transplantation	other-medical
,	O
cataract	other-medical
surgery	other-medical
,	O
glaucoma	other-medical
surgery	other-medical
,	O
and	O
surgery	O
to	O
repair	other-medical
retinal	other-medical
detachment	other-medical
)	O
.	O

CHMP	organization-government,governmentagency
had	O
concluded	O
that	O
the	O
marketing	O
authorizations	O
for	O
norfloxacin	other-medical
,	O
when	O
used	O
in	O
the	O
treatment	O
of	O
acute	O
or	O
chronic	other-disease
complicated	other-disease
pyelonephritis	other-disease
,	O
should	O
be	O
withdrawn	O
because	O
the	O
benefits	O
do	O
not	O
outweigh	O
their	O
risks	O
in	O
this	O
indication	O
.	O

The	O
label	O
states	O
,	O
``	O
When	O
pregnancy	O
is	O
detected	O
,	O
discontinue	O
Zestril	other-medical
as	O
soon	O
as	O
possible	O
.	O
''	O

In	O
May	O
2015	O
the	O
restaurant	O
manager	O
,	O
a	O
North	location-GPE
Korean	location-GPE
National	O
was	O
arrested	O
for	O
selling	O
illegal	O
Viagra	other-medical
and	O
Alcohol	other-chemicalthing
out	O
of	O
the	O
restaurant	O
.	O

In	O
Japan	location-GPE
,	O
Milnacipran	other-medical
is	O
used	O
in	O
the	O
treatment	O
of	O
Taijin	other-disease
kyofusho	other-disease
,	O
a	O
Japanese	location-GPE
variant	O
of	O
social	other-disease
anxiety	other-disease
disorder	other-disease
.	O

Propranolol	other-medical
is	O
a	O
blocker	O
for	O
the	O
beta-adrenergic	other-biologything
receptors	other-biologything
in	O
the	O
amygdala	O
which	O
usually	O
are	O
bound	O
to	O
by	O
stress	O
hormones	O
released	O
by	O
the	O
adrenal	other-biologything
gland-	other-biologything
epinephrine	other-biologything
and	O
norepinephrine	other-biologything
.	O

NIDA	organization-other
has	O
drawn	O
criticism	O
for	O
continuing	O
to	O
provide	O
funding	O
to	O
George	person-other
Ricaurte	person-other
,	O
who	O
in	O
2002	O
conducted	O
a	O
study	O
that	O
was	O
widely	O
touted	O
as	O
proving	O
that	O
MDMA	other-medical
(	O
ecstasy	O
)	O
caused	O
dopaminergic	O
neurotoxicity	other-disease
in	O
monkeys	O
.	O

``	O
First	O
described	O
by	O
Arocha-Pinango	person-other
and	O
Layrisse	person-other
in	O
Venezuela	location-GPE
in	O
1967	O
,	O
the	O
hemorrhagic	other-disease
diathesis	other-disease
caused	O
in	O
humans	O
by	O
touching	O
the	O
``	O
Lonomia	other-livingthing
``	O
species	O
begins	O
with	O
inflammatory	O
changes	O
at	O
the	O
site	O
of	O
envenoming	O
,	O
followed	O
by	O
systemic	O
symptoms	O
such	O
as	O
headache	other-medical
,	O
fever	other-medical
,	O
vomiting	other-medical
,	O
and	O
malaise	other-medical
.	O

In	O
the	O
early	O
hours	O
of	O
22	O
September	O
2015	O
,	O
Gray	person-other
and	O
fellow	O
South	O
Sydney	location-GPE
teammate	O
and	O
best	O
friend	O
Dylan	person-other
Walker	person-other
were	O
hospitalized	O
after	O
the	O
pair	O
overdosed	O
on	O
prescription	O
drugs	O
Oxycodone	other-medical
and	O
Tramadol	other-medical
at	O
Gray	person-other
's	O
apartment	O
in	O
Rosebery	location-GPE
.	O

Estrogen	other-medical
treatment	other-medical
upregulates	O
TRPV6	other-biologything
transcripts	O
by	O
8-fold	O
in	O
VDR	other-livingthing
KO	other-livingthing
mice	other-livingthing
and	O
by	O
4-fold	O
in	O
ovariectomized	other-livingthing
mice	other-livingthing
.	O

A	O
pooled	O
analysis	O
of	O
randomized	O
,	O
controlled	O
studies	O
of	O
meloxicam	other-medical
therapy	O
of	O
up	O
to	O
60	O
days	O
duration	O
found	O
that	O
meloxicam	other-medical
was	O
associated	O
with	O
a	O
statistically	O
significantly	O
lower	O
number	O
of	O
thromboembolic	other-medical
complications	other-medical
than	O
the	O
NSAID	other-medical
diclofenac	other-medical
(	O
0.2	O
%	O
versus	O
0.8	O
%	O
respectively	O
)	O
but	O
a	O
similar	O
incidence	O
of	O
thromboembolic	other-medical
events	O
to	O
naproxen	other-medical
and	O
piroxicam	other-medical
.	O

If	O
the	O
person	O
presents	O
symptoms	O
of	O
hyperthyroidism	other-medical
,	O
doctors	O
are	O
more	O
likely	O
to	O
test	O
for	O
Thyroid	other-biologything
stimulating	other-biologything
hormone	other-biologything
receptor	other-biologything
Antibodies	other-biologything
(	O
TRAb	other-biologything
)	O
,	O
and	O
monitor	O
the	O
effects	O
of	O
anti-thyroid	other-medical
therapy	O
,	O
also	O
associated	O
with	O
Graves	other-disease
'	other-disease
disease	other-disease
.	O